CSTLCastle Biosciences, Inc.
$33.18+40% 1Y
$33.18
$18.1552 weeks$43.04
Is the price fair?
What CSTL's price assumes
Castle Biosciences, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.03× revenue.
2.03
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.54
Price / book · as of 2026-Q2
- EV / sales
- 1.31
EV / sales
Details›
- Price / bookas of 2026-Q2
- 1.54
- EV / EBIToperating margin −9.0%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 1.31
- Market capitalisation30.5 million shares, counted Jul 23, 2026
- $1.01B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #10 of 21 by RyuScore